C61
Conditions
Interventions
Group 1: Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label.
Group 2: Adult male patients diagnosed with mCRPC and
Sponsors
Martin-Luther-Universität Halle-Wittenberg
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan or second line taxane based chemotherapy with cabazitaxel by treating physician as per local label. Written informed consent must be obtained prior to any data collection. After treatment decision enrollment is allowed for both treatment options before end of cycle 1.
Exclusion criteria
Exclusion criteria: Non-native German speakers who have insufficient language skills to complete the questionnaires. Severe cognitive limitations that do not allow filling out the questionnaires. Patients unable to consent or potentially unable to consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment satisfaction as assessed by an adapted version of the Lübeck Medications Satisfaction Questionnaire (LMSQ) | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of achieving personal treatment goals using the the Self-Developed Personal treatment goal questionnaire (PTGQ) Prostate cancer therapy-specific quality of life as assessed by the Functional Assessment of Cancer Therapy Prostate (FACT-P) Overall quality of life and treatment experience, measured by a combined evaluation of LMSQ, PTGQ, and FACT-P until end of therapy (either lutetium (177Lu) vipivotide tetraxetan or cabazitaxel) | — |
Countries
Germany
Contacts
Public ContactAlexander Heinzel
Abteilung für Nuklearmedizin, Universitätsmedizin Halle (Saale)
Outcome results
None listed